



December 13, 2021

Omega Medical Imaging, LLC  
% Mr. John Newman  
Regulatory Specialist  
3400 St. Johns Parkway, Suite 1020  
SANFORD FL 32771

Re: K212890

Trade/Device Name: Nyquist.IQ  
Regulation Number: 21 CFR 892.1650  
Regulation Name: Image-intensified Fluoroscopic X-ray System  
Regulatory Class: Class II  
Product Code: JAA, MQB  
Dated: November 10, 2021  
Received: November 12, 2021

Dear John Newman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmnmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part

801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email ([DICE@fda.hhs.gov](mailto:DICE@fda.hhs.gov)) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

, for

Thalia T. Mills, Ph.D.  
Director  
Division of Radiological Health  
OHT7: Office of In Vitro Diagnostics  
and Radiological Health  
Office of Product Evaluation and Quality  
Center for Devices and Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known)  
K212890

Device Name  
Nyquist.IQ

Indications for Use (Describe)

The Omega Medical Imaging, LLC Nyquist.IQ Image Processor is intended for use in Radiographic/fluoroscopic applications including cardiac, vascular, general radiographic/fluoroscopic diagnostic, and interventional x-ray imaging. The Nyquist.IQ is intended solely to be integrated only with Omega Medical Imaging CS-series-FP Systems.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

**\*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\***

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services  
Food and Drug Administration  
Office of Chief Information Officer  
Paperwork Reduction Act (PRA) Staff  
[PRASStaff@fda.hhs.gov](mailto:PRASStaff@fda.hhs.gov)

*"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."*



## **Traditional 510(k) SUMMARY**

K212890

Company Name: Omega Medical Imaging, LLC  
Address: 3400 St. Johns Parkway, Suite 1020, Sanford, FL 32771  
Telephone No: 407-323-9400  
Registration No: 1052701  
Contact person: John Newman (Regulatory Affairs Specialist)  
Date Prepared: 09/02/2021  
Device (trade) name: Nyquist.IQ  
Common/usual name: Image Processor  
Classification Name: Image Processor  
Classification Panel: Radiology  
CFR section: 892.1650  
Device Class: Class II  
Primary Product code: JAA  
Secondary product code: MQB

## **Predicate Device K182834**

Company Name: Omega Medical Imaging, LLC  
Address: 3400 St. Johns Parkway, Suite 1020  
Telephone No: 407-323-9400  
Registration No: 1052701  
Contact person: John Newman  
Date Prepared: 03/29/2019  
Device (trade) name: CS-series-FP with Optional Accessory Device CA-100S (FluoroShield)  
Common/usual name: Fluoroscopic/Radiographic X-ray system  
Classification Name: System, X-Ray, Fluoroscopic, Image -Intensified  
Classification Panel: Radiology  
CFR section: 892.1650  
Device Class: Class II  
Primary Product code: JAA  
Secondary Product code: OWB

## Reference Predicate Device K121293

Company Name: Omega Medical Imaging, LLC  
Address: 675 Hickman Circle, Sanford, FL 32771  
Telephone No: 407-323-9400  
Registration No: 1052701  
Contact person: John Newman  
Date Prepared: 04/20/2012  
Device (trade) name: CS-series-FP with 3030+ Option  
Common/usual name: Fluoroscopic/Radiographic X-ray system  
Classification Name: System, X-Ray, Fluoroscopic, Image -Intensified  
Classification Panel: Radiology  
CFR section: 892.1650  
Device Class: Class II  
Primary Product codes: JAA  
Secondary Product code: OWB

### Indication: of use

The Omega Medical Imaging, LLC CS Image Processor is a Radiographic/fluoroscopic applications including cardiac, vascular, diagnostic, and interventional x-ray imaging.

The Nyquist.IQ is intended solely with the Omega Medical Imaging CS

### Device description:

Nyquist.IQ is a dynamic processor. The system application is based on a PCT based software performing image processing and true storage. The DICOM compliant connectivity provides patient demographics, examination, and image data digitally.

Nyquist.IQ is not a standalone device, but functions as a component for the Omega medical CS platform. Nyquist IQ is an image processor that acquires image data from the Omega medical CS

The Nyquist.IQ operates in connection with the Varex s 3030. This is demonstrated in the substantial equivalence study of the Omega CS-FP with Optional Accessory /DFW/CSA field platform.

The Nyquist.IQ is intended solely with Omega Medical Imaging Systems. The Nyquist.IQ provides fundamental performance characteristics. The Nyquist.IQ interventional fluoroscopy procedure consists of:

- Realtime image visualization of patient anatomy during
- Imaging techniques and tools to assist interventional procedures
- Postprocessing functions after interventional procedures.
- Storage of reference/control images for patient records.
- Compatibility to images of other modalities via DICOM
- Compatibility with already FDA cleared FluoroShield AI Exposure Reduction Technology (K182834)

This array of functions provides the physician the imaging information for invasive interventional procedures.

The Nyquist.IQ images are available also in P-5000 configuration and is similar to marketed and predicate device Omega Medical Imaging Systems / FluoroShield Device

### Patient Population

General Population concerns must be taken for pediatric use.

Based on the information provided, the device is considered substantially equivalent to the current marketed predicate device Omega Medical Imaging Systems / FluoroShield Device share the same indication

### Technological characteristics

The Nyquist.IQ system has similar technological characteristics compared to predicate device. Below are the key improvements to it. Below are the key improvements to the predicate device.

- Integration of a New Flat Panel Detector (True Flat Panel) with the already FDA cleared FluoroShield AI Exposure Reduction Technology

The difference between the device and the predicate device does not raise concerns regarding safety or effectiveness. The information provided by the device is considered substantially equivalent to the predicate device Omega Medical Imaging Systems / FluoroShield Device of fundamental technology

## Summary of Nonclinical Performance

Nonclinical performance testing has been performed in accordance with the following International and FDA approved consensus documents:

1. IEC 62304 Medical device software life cycle processes (Edition 1.0, 6/20/05) FDA/CDRH recognition number 13
2. ISO 14971 Medical application of risk management to medical devices (2007) FDA/CDRH recognition number 5
3. Guidance for Industry Guidance for the Content of premarket Submissions for Software Contained in Medical Devices (draft, May 2005) FDA/CDRH recognition number 337).
4. Guidance for Industry FDA Staff Program: Evaluating Substantial Equivalence for Premarket Notifications [510(k)], July 28, 2014 (document number 14-06)

Software verification testing of functional requirements, as well as performance, reliability, and safety, have been performed to verify that all conditions specified in the specifications, as well as the safety risk control measures from the privacy and security requirements, have been implemented. A successful verification test was passed.

Nonclinical validation testing has been performed to ensure that the device conforms to the intended use and user needs, effectively satisfying the instruction for use.

The device does not require clinical study data since substantial equivalence to the predicate device, the Optima Accessory Device / FluoroShield, has been demonstrated with the following attributes:

- Indication for use.
- Technological characteristics.
- Nonclinical performance testing; and
- Safety and effectiveness.

### Substantial Equivalence Conclusion:

The device is substantially equivalent to the predicate device in terms of indications for use, technological characteristics, safety and effectiveness.

The device is within the controls and predetermined conditions specified in the premarket notification. The device demonstrates that it complies with the use requirements and the requirements specified in the FDA standards and documents.

Therefore, the device is safe and effective as its predicate device and does not raise any safety and/or effectiveness concerns.

Comparison with Predicate Devices:

		Indications for use comparison:	
510(k) Number and Device Name	K121293 (Ref. Predicate Device) CS-series-FP with 3030+ option	K182834 (Predicate Device) CS-series-FP with Optional Accessory Device CA-100S / FluoroShield	(This Submission) Nyquist.IQ
Intended Use	The Omega Medical Imaging, LLC CS-series-FP with 3030+ Option systems are intended for use in radiographic/fluoroscopic applications including cardiac, vascular, general radiographic/fluoroscopic diagnostic, and interventional X-Ray imaging.	The Omega Medical Imaging, LLC CS-series-FP (SSXI) systems with optional accessory device CA-100S as a modification device to provide an automated Region of interest that manages exposure to the patient and operator. The system is intended for use in Radiographic/fluoroscopic applications including cardiac, vascular, general radiographic/fluoroscopic diagnostic, and interventional x-ray imaging for General Populations. At no time will the CA-100S be considered as a replacement for the primary collimator. The primary collimator shall always be used, in accordance with good medical practice, to define a Region of Interest	The Omega Medical Imaging, LLC IPS-100, Nyquist.IQ Image Processor is intended for use in Radiographic/fluoroscopic applications including cardiac, vascular, general radiographic/fluoroscopic diagnostic, and interventional X-Ray imaging. (The Nyquist.IQ is intended solely to be integrated only with Omega Medical Imaging CS-series-FP systems.)
Classification Name:	Image-intensified Fluoroscopic X-ray system	Image-intensified Fluoroscopic X-ray system	Image-intensified Fluoroscopic X-ray system
CFR Regulation #:	892.1650	892.1650	892.1650
Device Class	Class II	Class II	Class II
Classification Product Code:	JAA, OWB	JAA, OWB	JAA, MQB

PRODUCT OVERVIEW

Substantial Equivalence:

Detailed in the Bench testing section of this submission.

Safety information:

- The Omega Medical Imaging Processor consists with the applicable requirements of 21 CFR 820.
- The Omega Medical Imaging Processor is in compliance with the international safety standards IEC 60601-2, EN ISO 11522, EN ISO 14971.
- The Omega Medical Imaging Processor comply with ULd 60601/USA C2-2.2 Noise M90.
- The device is designed and manufactured under a Quality Management System in accordance with ISO 9001 and ISO 13485 Standards. This device is in compliance with applicable standards and its collateral standards. All requirements of the FDA 21 CFR 820, that apply to this device will be met and maintained.



# Safety is assured through a risk management process and manufacturing System Regulations

## Referenced Guidance Documents:

- Guidance for this submission of 510(k) for Indications of use as provided in: Pediatric Information for X-ray Imaging Device Premarket Notifications (Document issued on November 28<sup>th</sup>, 2017) Guidance for Industry and Food and Drug Administration Staff.
- Guidance for the Content of Premarket Submissions for Management of Cybersecurity in Medical Devices. (Document issued on October 2018)
- Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices (Document issued on May 11, 2005)
- Guidance for Industry and FDA Staff: Information to Support a Claim of Electromagnetic Compatibility (EMC) of Electrically -powered Medical Devices. (Document issued on July 11, 2016)
- Guidance for this submission of 510(k) for (SSXID) Solid State X-ray Imaging Devices issued on: September 1, 2016 was used to establish substantial equivalence
- Guidance for industry and FDA Staff - User Fees and Refunds for Premarket Notification Submissions 510(k)s, (Document issued on October 2, 2017)
- Guidance for industry and FDA Staff - Refuse to Accept Policy for 510(k) (Document issued on September 2019)
- Guidance for industry and FDA Staff -Format for Traditional and Abbreviated 510(k)s (Document issued on September 2019)
- Guidance for industry and FDA Staff - Deciding when to submit a 510(k) for a change to an existing device. (Document issued on October 25, 2017)
- Guidance for industry and FDA Staff - The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)] (Document Issued on July 28, 2014)
- Guidance for industry and FDA Staff - Guidance for Off -The-Shelf Software Use in Medical Devices (Document issued on September 2019)
- Guidance for industry and FDA Staff - Guidance for the Content of Premarket Submission for Software in Medical Devices. (Document issued May 11<sup>th</sup>, 2005)
- Guidance for industry and Food and Drug Administration Staff - Policy Clarification for Certain Fluoroscopic Equipment Requirements (Document issued on May 8, 2019)
- Guidance for Industry and FDA Staff - Medical X-Ray Imaging Devices Conformance with IEC Standards. (Document issued on May 8, 2019)
- Guidance for Industry and FDA Staff - Clarification of Radiation Control Regulations for Manufacturers of Diagnostic X -Ray Equipment. (Document issued on December 17, 2018)
- Guidance for Industry and FDA Staff - Guidance for the submission of 510(k)s for Solid state X -ray Imaging Devices. (Document issued on September 1, 2016)